Zafar Andleeb, Aslanides Ioannis M, Selimis Vasileios, Tsoulnaras Konstantinos I, Tabibian David, Kymionis George D
Emmetropia Mediterranean Eye Institute, Heraklion, Greece.
Department of Ophthalmology, University Hospital of Heraklion "PAGNI", Heraklion, Greece.
Case Rep Ophthalmol. 2018 Feb 14;9(1):143-148. doi: 10.1159/000486924. eCollection 2018 Jan-Apr.
We report here the case of a patient with anterior segment migration of intravitreal dexamethasone implant as well as its management and outcome.
The patient had the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence of macular edema treated with repeated intravitreal dexamethasone implant.
Dexamethasone implant had completely dissolved from the eye 12 weeks after insertion without any complication.
A conservative approach with regular monitoring in the situation of a quiet anterior segment without any corneal decompensation can provide enough time for the implant to dissolve without causing any complication to the involved eye, avoiding any additional surgical intervention, as presented in this case report. Despite the fact that the implant was left for natural dissolution, there were no adverse effects related to the graft or the eye.
我们在此报告一例玻璃体内地塞米松植入物前段移位的病例及其处理方法和结果。
该患者经历了以下一系列事件:复杂白内障手术、虹膜缝合人工晶状体植入,随后玻璃体内注射阿瓦斯汀治疗黄斑囊样水肿,玻璃体内植入地塞米松治疗视网膜静脉阻塞,行Descemet膜剥脱自动内皮角膜移植术(DSAEK)治疗角膜失代偿,最后反复玻璃体内植入地塞米松治疗黄斑水肿复发。
地塞米松植入物在插入后12周已完全从眼中溶解,无任何并发症。
如本病例报告所示,在前段安静且无角膜失代偿的情况下,采用定期监测的保守方法可为植入物溶解提供足够时间,而不会对患眼造成任何并发症,避免了任何额外的手术干预。尽管植入物任其自然溶解,但未出现与移植物或眼睛相关的不良反应。